NEW YORK, November 22, 2016 /PRNewswire/ --
This morning, Stock-Callers.com has lined up the following healthcarestocks for assessment following a positive Monday's session where gains were broad based as all nine sectors ended the session in green: Perrigo Company PLC (NYSE: PRGO), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Supernus Pharmaceuticals Inc. (NASDAQ:
On Monday, shares in Dublin, Ireland headquartered Perrigo Co. PLC ended the session 1.33% higher at $89.31 with a total volume of 924,566 shares traded. Shares of Perrigo, which together with its subsidiaries, develops, manufactures, markets, and distributes over-the-counter (OTC) consumer goods and pharmaceutical products worldwide, are trading 0.95% below its 50-day moving average and 12.62% below its 200-day moving average. Moreover, the Company's shares have a Relative Strength Index (RSI) of 51.81.
On November 11th, 2016, research firm Bank of America/ Merrill upgraded the Company's stock rating from 'Underperform' to 'Neutral'. Visit us today and download your complete report on PRGO for free at: http://stock-callers.com/registration/?symbol=PRGO
Parsippany, New Jersey headquartered Pacira Pharmaceuticals Inc.'s stock finished Monday's session 2.64% lower at $35.05 with a total volume of 737,906 shares traded. Pacira Pharmaceuticals' shares have advanced 4.32% in the past one month. Shares of the Company, which develops, commercializes, and manufactures proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the US, are trading below its 50-day and 200-day moving averages by 1.36% and 20.80%, respectively. Pacira Pharmaceuticals' stock has an RSI of 49.89.
On November 03rd, 2016, research firm Mizuho reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $64 a share to $46 a share. The complimentary research report on PCRX can be accessed at: http://stock-callers.com/registration/?symbol=PCRX
On Monday, shares in Rockville, Maryland-based Supernus Pharmaceuticals Inc. recorded a trading volume of 523,648 shares. The stock ended the day flat at $22.25. Shares of the Company, which focuses on the development and commercialization of products for the treatment of central nervous system diseases in the US, are trading at a PE ratio of 43.63. The Company is trading above its 200-day moving average by 15.50%. Furthermore, shares of Supernus Pharma have an RSI of 51.18. Register for free on Stock-Callers.com and download the PDF research report on SUPN at: http://stock-callers.com/registration/?symbol=SUPN
Waltham, Massachusetts headquartered PerkinElmer Inc.'s stock advanced 1.26%, to close the day at $50.58. The stock recorded a trading volume of 534,063 shares. Shares of the Company, which provides products, services, and solutions to the diagnostics, research, environmental, industrial, and laboratory services markets worldwide, are trading 4.22% and 2.87% below its 50-day and 200-day moving averages, respectively. Additionally, the stock traded at a PE ratio of 23.88 and has an RSI of 43.48. Get free access to your research report on PKI at: http://stock-callers.com/registration/?symbol=PKI
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://stock-callers.com/legal-disclaimer/
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Find out about travel shots or vaccination before you travel to your destination country. Travel ...
Hay fever is caused by allergy to pollen and is characterized by runny or blocked nose, sneezing, ...
Therapeutic drug monitoring is measuring drug concentrations at specific intervals in a patient's ...View All